Reduction of age-associated arterial wall changes by low-dose valsartan

European Journal of Preventive Cardiology

Volumn 19, Issue 6, 2012, Pages 1243-1249

  Lunder, Mojca ^a   Janić, Miodrag ^a   Šabovič, Mišo ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Arterial ageing; arterial stiffness; cardiovascular prevention; early prevention; endothelial function; middle aged males

Indexed keywords

PLACEBO; VALSARTAN;

ADULT; ARTERIAL STIFFNESS; ARTERY DILATATION; ARTERY DISEASE; ARTERY WALL; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; COMMON CAROTID ARTERY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FLOW MEDIATED DILATION; FOLLOW UP; HUMAN; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; ULTRASOUND;

ADULT; AGE FACTORS; AGING; ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; BRACHIAL ARTERY; CAROTID ARTERY, COMMON; DOUBLE-BLIND METHOD; HEART RATE; HUMANS; MALE; PULSE WAVE ANALYSIS; SLOVENIA; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VALINE; VASCULAR DISEASES; VASCULAR STIFFNESS; VASODILATION;

EID: 84873916138     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/1741826711423104     Document Type: Article

References (29)

1. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a 'set up' for vascular disease. Circulation. 2003 ; 107 (1). 139-146
2. Wilkinson IB, Franklin SS, Cockcroft JR. Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology. Hypertension. 2004 ; 44 (2). 112-116
3. Najjar SS, Scuteri A, Lakatta EG. Arterial aging: is it an immutable cardiovascular risk factor?. Hypertension. 2005 ; 46 (3). 454-462
4. Fitzpatrick P, Fitz-Simon N, Lonergan M, Collins C, Daly L. Heartwatch: the effect of a primary care-delivered secondary prevention programme for cardiovascular disease on medication use and risk factor profiles. Eur J Cardiovasc Prev Rehabil. 2011 ; 18 (1). 129-135
5. Nery AB, Mesquita ET, Lugon JR, Kang HC, de Miranda VA, de Souza BG, et al. Prehypertension and cardiovascular risk factors in adults enrolled in a primary care programme. Eur J Cardiovasc Prev Rehabil. 2011 ; 18 (2). 233-239
6. Broekhuizen LN, Boekholdt SM, Arsenault BJ, Despres JP, Stroes ES, Kastelein JJ, et al. Physical activity, metabolic syndrome, and coronary risk: the EPIC-Norfolk prospective population study. Eur J Cardiovasc Prev Rehabil. 2011 ; 18 (2). 209-217
7. Cohn JN. Role of the renin-angiotensin system in cardiovascular disease. Cardiovasc Drugs Ther. 2010 ; 24 (4). 341-344
8. Wang M, Zhang J, Spinetti G, Jiang LQ, Monticone R, Zhao D, et al. Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats. Am J Pathol. 2005 ; 167 (5). 1429-1442
9. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006 ; 114 (25). 2850-2870
10. Neutel JM. Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens. 2004 ; 18 (9). 599-606
11. Weintraub HS, Basile J. The pleiotropic effects of antihypertensive agents: do they account for additional cardiovascular benefit beyond BP reduction?. South Med J. 2008 ; 101 (8). 818-823
12. Schieffer B, Bunte C, Witte J, Hoeper K, Boger RH, Schwedhelm E, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 2004 ; 44 (2). 362-368
13. Su KH, Tsai JY, Kou YR, Chiang AN, Hsiao SH, Wu YL, et al. Valsartan regulates the interaction of angiotensin II type 1 receptor and endothelial nitric oxide synthase via Src/PI3K/Akt signalling. Cardiovasc Res. 2009 ; 82 (3). 468-475
14. Yoshida Y, Fukuda N, Maeshima A, Yamamoto C, Matsumoto A, Ueno T, et al. Treatment with valsartan stimulates endothelial progenitor cells and renal label-retaining cells in hypertensive rats. J Hypertens. 2011 ; 29 (1). 91-101
15. Prasad A, Quyyumi AA. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation. 2004 ; 110 (11). 1507-1512
16. Ono H, Saitoh M, Ono Y, Ishimitu T, Matsuoka H. Imidapril improves L-NAME-exacerbated nephrosclerosis with TGF-beta 1 inhibition in spontaneously hypertensive rats. J Hypertens. 2004 ; 22 (7). 1389-1395
17. Lunder M, Janic M, Habjan S, Sabovic M. Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males - a pilot study. Atherosclerosis. 2011 ; 215 (2). 446-451
18. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992 ; 340 (8828). 1111-1115
19. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002 ; 39 (2). 257-265
20. Lekakis J, Abraham P, Balbarini A, Blann A, Boulanger CM, Cockcroft J, et al. Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil. 2011 ;:
21. Olthof MR, Bots ML, Katan MB, Verhoef P. Effect of folic acid and betaine supplementation on flow-mediated dilation: a randomized, controlled study in healthy volunteers. PLoS Clin Trials. 2006 ; 1 (2). e10.
22. Sugawara J, Tarumi T, Tanaka H. Effect of mirthful laughter on vascular function. Am J Cardiol. 2010 ; 106 (6). 856-859
23. Fahs CA, Smith DL, Horn GP, Agiovlasitis S, Rossow LM, Echols G, et al. Impact of excess body weight on arterial structure, function, and blood pressure in firefighters. Am J Cardiol. 2009 ; 104 (10). 1441-1445
24. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J. 2010 ; 31 (19). 2338-2350
25. Saisho Y, Komiya N, Hirose H. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan. Diabetes Res Clin Pract. 2006 ; 74 (2). 201-203
26. Ridker PM, Danielson E, Rifai N, Glynn RJ. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension. 2006 ; 48 (1). 73-79
27. Plum J, Bunten B, Nemeth R, Grabensee B. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol. 1998 ; 9 (12). 2223-2234
28. Karalliedde J, Smith A, DeAngelis L, Mirenda V, Kandra A, Botha J, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension. 2008 ; 51 (6). 1617-1623
29. Kosch M, Levers A, Lang D, Bartels V, Rahn KH, Pavenstadt H, et al. A randomized, double-blind study of valsartan versus metoprolol on arterial distensibility and endothelial function in essential hypertension. Nephrol Dial Transplant. 2008 ; 23 (7). 2280-2285